We’re reading about China’s GLP-1 drugs, a puzzling FDA rejection
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding…
Consumer group presses U.S. to authorize generic GLP-1s
Public Citizen petitioned the Trump administration to use a federal law to authorize generic competitors for GLP-1 drugs…
Hims is in the crosshairs. What does it mean for compounding?
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Hims & Hers compounder received FDA warning letter| STAT
The Food and Drug Administration late last year issued a warning letter to MedisourceRx, a compounding pharmacy owned…
Updated CMS data reshapes Medicare Advantage risk scores
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
As telehealth firms market multi-cancer tests, doctors are wary
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Novo Nordisk says Hims & Hers’ cheaper version of Wegovy pill is illegal
In an unexpected move, Hims & Hers is making available a cheaper, compounded version of the Wegovy weight…
Epic launches AI Charting, scrambling the ambient scribe market
The nation’s largest electronic health record company, Epic Systems, announced on Wednesday more details around its long-anticipated AI…
Marty Makary addresses staff concerns over drug voucher program
WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff…
UnitedHealth shrinks, Medicare Advantage crackdown: Health Care Inc.
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
Senators raise concerns about TrumpRx in letter to HHS watchdog
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…